Boryung said on the 28th that it will launch the combination drug Kanarbjet, which treats hypertension and dyslipidemia together, on the 1st of next month.
Kanarbjet is a triple combination that adds the cholesterol-lowering agents atorvastatin and ezetimibe to the hypertension treatment Kanarb (ingredient name: fimasartan). It is designed to manage blood pressure and low-density lipoprotein (LDL) cholesterol at the same time.
The main targets are patients with metabolic syndrome who have both hypertension and dyslipidemia, and high-risk patients who have not reached their cholesterol goals with statin monotherapy alone.
In Korea, about 72% of patients with hypertension are known to have accompanying dyslipidemia, increasing the importance of treatment strategies that manage both conditions together.
Boryung also held a launch symposium on the 21st and shared ways to apply the drug in real clinical settings. Lee Chan-joo, a professor at Yonsei University College of Medicine who participated as a speaker, said, "A treatment strategy that controls blood pressure and cholesterol together will help reduce the risk of cardiovascular disease."
Since launching Kanarb, the nation's first new hypertension drug, in 2011, Boryung has expanded the Kanarb Family of combination drugs based on it. To date, it has secured about 73,000 cases of clinical data.
The company said it plans to develop a quadruple combination and a hypertension-diabetes combination, among others, to expand its presence in chronic disease treatment.
Sung Baek-min, executive vice president and head of BD & Marketing at Boryung, said, "Through Kanarbjet, we are providing a new treatment option for patients and medical staff," and added, "We will strengthen our market competitiveness based on the accumulated data."